<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137695</url>
  </required_header>
  <id_info>
    <org_study_id>DEFCon2</org_study_id>
    <nct_id>NCT01137695</nct_id>
  </id_info>
  <brief_title>Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus</brief_title>
  <official_title>Symlin® Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cheryl Rosenfeld, DO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>North Jersey Endocrine Consultants, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the study is that those obese patients with type 2 diabetes mellitus who do
      not respond to the FDA approved dose of 120 mcg of pramlintide (Symlin®) 3 times daily with
      expected glucose control require higher than FDA approved dosage.

      The primary objective of the study is to determine whether higher doses of pramlintide
      (Symlin®) in patients with type 2 diabetes mellitus control glucose better than the FDA
      approved dose of 120 mcg three times daily.

      The secondary objectives include proving whether higher dose pramlintide (Symlin®) is more
      efficacious in causing weight loss and reduction in waist circumference than standard dose
      pramlintide (Symlin®),to determine whether blood levels of certain hormones correlate with
      need for higher dose therapy,and to determine whether or not the rate of common adverse
      effects exceeds the maximum FDA approved pramlintide (Symlin®) dose of 120 mcg three times
      daily.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose control</measure>
    <time_frame>6 months</time_frame>
    <description>A1c Fasting plasma glucose Post-prandial glucose Glycomark</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>6 months</time_frame>
    <description>Weight, BMI, Waist circumference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amylin level</measure>
    <time_frame>initial</time_frame>
    <description>does initial blood amylin level correlate with need for higher dose pramlintide?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon level</measure>
    <time_frame>6 months</time_frame>
    <description>Does change in glucagon level correlate with glycemic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>6 months</time_frame>
    <description>Whether or not the rate of common adverse effects exceeds the maximum FDA approved pramlintide (Symlin®) dose of 120 mcg TID (as compared to the clinical practice study) - GI: nausea 30% and Hypoglycemia: medically assisted 0.7% or patient ascertained 0.7%.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Symlin Naive, Usual Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symlin 120 mcg three times daily in patients not previously treated with pramlintide before the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symlin Naive, Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation of pramlintide dose to 360 mcg three times daily in patients not taking pramlintide prior to study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symlin treated, Usual Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pramlintide 120 mcg three times daily in patients who have been treated with pramlintide 120 mcg prior to the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symlin Treated, Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pramlintide 360 mcg three times daily in patients previously treated with 120 mcg prior to the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramlintide</intervention_name>
    <description>120 mcg SQ three times daily for 6 months.</description>
    <arm_group_label>Symlin Naive, Usual Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramlintide</intervention_name>
    <description>360 mcg SQ three times daily for 6 months</description>
    <arm_group_label>Symlin Naive, Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramlintide</intervention_name>
    <description>120 mcg SQ three times daily for 6 months</description>
    <arm_group_label>Symlin treated, Usual Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramlintide</intervention_name>
    <description>360 mcg SQ three times daily for 6 months</description>
    <arm_group_label>Symlin Treated, Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years.

          2. Type 2 diabetes mellitus.

          3. Obese (BMI &gt; 30 kg/m2), waist circ. &gt;35&quot; women, &gt;40&quot; men.

          4. Basal insulin plus at least 2 injections of mealtime insulin daily or pre-mixed
             insulin.

          5. On stable insulin dose for at least 3 mos (baseline + 20%, no minimum).

          6. If pramlintide treated, on stable full dose for at least 3 months.

          7. A1c &gt; 7.0% and &lt; 9.0%.

          8. Women of childbearing age if using a reliable form of birth control.

          9. Women of childbearing age if post tubal ligation or surgical menopause.

         10. Able to consent.

         11. Willing to perform self-monitoring of glucose.

         12. Willing to attend study visits.

         13. Written informed consent to participate in the study.

         14. Agreement to maintain prior diet and exercise throughout the full course of the study.

        Exclusion Criteria:

          1. Age &lt;18 or &gt;80 years.

          2. Confirmed gastroparesis or taking medications affecting gastric motility.

          3. A1c &lt;7.0% or &gt;9.0%.

          4. Recurrent severe hypoglycemia or hypoglycemic unawareness.

          5. CHF.

          6. Creatinine clearance &lt;30 ml/min.

          7. History of MI &lt;6 mos prior to enrollment.

          8. History of ventricular arrhythmia.

          9. History of cancer or chemotherapy &lt;6 mos prior to enrollment.

         10. Laboratory abnormalities as follows:

               1. Liver enzymes &gt;3X ULN.

               2. Hematocrit less than 30.

               3. Serum creatinine &gt;2.5 mg/dl.

               4. Fasting triglycerides &gt;500 mg/dl.

         11. Cirrhosis.

         12. Pregnancy or nursing.

         13. Inability to provide consent.

         14. Unwilling to attend study visits.

         15. Unwilling to perform self-monitoring of glucose.

         16. Chronic oral or parenteral glucocorticoid therapy (over one week of treatment) within
             3 months prior to screening.

         17. Investigational drug treatment within 3 months prior to screening.

         18. Donation of blood, significant blood loss or transfusion within 3 months of screening.

         19. History of acromegaly or Cushing's syndrome.

         20. Use of prohibited concomitant medications.

         21. Type 1 diabetes mellitus.

         22. Acute metabolic complication (hyperosmolar state) &lt;6 months prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheryl Rosenfeld, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Jersey Endocrine Consultants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Rothman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Physicians Group Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Schorr, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Mary Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Jersey Endocrine Consultants</name>
      <address>
        <city>Denville</city>
        <state>New Jersey</state>
        <zip>07834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Physicians Group</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>October 13, 2011</last_update_submitted>
  <last_update_submitted_qc>October 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>North Jersey Endocrine Consultants, LLC</investigator_affiliation>
    <investigator_full_name>Cheryl Rosenfeld, DO</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pramlintide</keyword>
  <keyword>glucose</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>amylin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

